Chronic granulomatous diseases caused by Nocardia seriolae have resulted in substantial economic losses for the aquaculture industry. DNA vaccines are considered a promising approach for controlling infectious diseases. To develop effective DNA vaccines against N. seriolae, we selected Ag85L, MmaA4, HspX, Rv3407, and HtpG as candidate antigens. Among these, pcDNA-Ag85L and pcDNA-MmaA4 were the most effective against N. seriolae infection in largemouth bass (Micropterus salmoides), achieving the highest relative percentage survival (RPS) rates of 78.6 % and 92.9 %, respectively. Tissue bacterial loads and histopathological tests revealed a significant reduction in bacterial abundance in the liver, spleen, head kidney, and trunk kidney of the immunised groups compared to that in the control group. Additionally, no distinct pathological changes were observed in the spleen or head kidney tissues. The expression levels of immune-related genes including IL-1β, IL-8, MHCI, MHCII, CD4, and CD8α were significantly upregulated in the pcDNA-Ag85L and pcDNA-MmaA4 immunised groups, thus indicating that the two DNA vaccines mediated immune protection by promoting both humoral and cellular immune responses. Overall, the pcDNA-Ag85L and pcDNA-MmaA4 DNA vaccines demonstrated strong potential for protecting largemouth bass against N. seriolae infection, offering an innovative solution for controlling granulomatous diseases in fish.